In 1969 Li and Fraumeni identified, from a systematic study of 648 children with rhabdomyosarcomas, five families in which a sibling or a cousin was affected by sarcoma (Li and Fraumeni, 1969a, b) . A prospective study of four of the original families indicated that there was a significantly increased risk of cancer within these families, particularly premenopausal breast cancer, as well as a significant excess of second malignancies (Li and Fraumeni, 1982) . The term 'Li-Fraumeni syndrome' was used initially by Pearson et al (1982) and is now the most common term for this dominant inherited cancer syndrome. Studies from our own group on a population-based series of children with soft-tissue sarcoma (Birch et al, 1984; 1990 ) and a USA hospital-based series of survivors of childhood soft-tissue sarcomas from Strong's group in the USA confirmed that the familial clustering was due to inherited predisposition and not to environmental factors. Twenty-four families, defined using strict criteria, were subsequently studied by the Li and Fraumeni groups (Li et al, 1988) . Such families are now regarded as having 'classic' Li-Fraumeni syndrome (LFS), namely a proband aged under 45 years with a sarcoma having a first-degree relative aged under 45 years with any cancer and an additional first-or second-degree relative aged under 45 years in the same lineage with any cancer or a sarcoma at any age (Li et al, 1988) . This study by Li et al (1988) indicated that the spectrum of tumours within the syndrome included acute leukaemia, premenopausal breast carcinoma, brain and adrenocortical tumours as well as bone and soft-tissue sarcomas. Other studies have indicated that a number of other cancers may occur at an increased frequency in these families, notably melanoma, germ cell tumours, Wilms' tumours, gastric and pancreatic carcinomas and lung cancer (Hartley et al, 1987;  1989; Varley et al, 1995; 1997a) .
While the definition of classic LFS has become generally accepted, a number of groups have relaxed the description to include incomplete Li-Fraumeni syndrome (a proband with an affected first-degree relative; Brugieres et al, 1993) and LiFraumeni-like syndrome (LFL). Two groups have defined LFL families independently but using different criteria. Eeles (1995) defined LFL as a clustering of two different tumours (both characteristic of LFS) in individuals who are first-or second-degree relatives of any age. Our own group has defined LFL by more stringent criteria: a proband with any childhood tumour or sarcoma, brain tumour or adrenocortical tumour under 45 years plus a first-or second-degree relative with a typical LFS tumour at any age and another first-or second-degree relative with any cancer under the age of 60 (Birch et al, 1994a) . In the following discussions, we refer to LFL families using the definition of Birch et al (1994a) .
The rarity of classic LFS families plus the high mortality within those families precluded a linkage study to identify the likely chromosomal location of the causative genetic defect. Malkin et al (1990) therefore adopted a candidate gene approach and analysed the tumour-suppressor gene TP53. This gene was chosen because mutations within TP53 had been identified in many tumour types, including those commonly associated with Li-Fraumeni syndrome. In addition, studies from transgenic mouse models had indicated that germline mutation to TP53 was associated with an elevated incidence of sarcomas, lymphoid malignancies, lung and adrenal tumours (Lavigueur et al, 1989) . In their original report, Malkin et al (1990) studied five LFS families, all of whose members had mutations within the TP53 gene. THE TP53 GENE TP53 was first identified in 1979 as a gene encoding a protein that complexes to the large T antigen of SV40 (Lane and Crawford, 1979; Linzer and Levine, 1979) . A number of properties initially assigned to the TP53 protein, including the ability to immortalize cells (Jenkins et al, 1984) and to transform primary rat embryo fibroblasts in cooperation with ras (Eliyahu et al, 1984; Parada et al, 1984) , indicated that it was a dominantly acting oncogene. Mutation to TP53 was found to enhance its transformation efficiency, a finding compatible with the hypothesis that TP53 is a cellular oncogene that can be activated by mutation (Jenkins et al, 1985) . However, a number of observations indicated that the 'wild-type' TP53 proteins that had the properties of oncogenes were in fact mutant, and more detailed studies showed that the wild-type protein could not cooperate with ras, and indeed could actually suppress transformation by mutant TP53 and ras (Finlay et al, 1989) . Furthermore, TP53 was shown to be lost or inactivated in a number of malignancies, both human and murine, and is now known to be the most frequently altered gene in human tumours (Hollstein et al, 1991; Levine et al, 1991) . There are currently over 4500 reports of somatic mutation in TP53 in human tumours (Hollstein et al, 1996) and, although the mutations spread over essentially the entire gene, there is considerable clustering of mutations within the central region of the protein. The majority of mutations are missense, with alterations at only five codons representing 25% of all known mutations (codons 175, 245, 248, 249 and 273; Hollstein et al, 1996) .
TP53 is now known to possess a spectrum of properties, including transcriptional activation and repression via sequencespecific DNA binding to specific target sequences. Sequences at Eeles et al (1993) Sun et al (1996) Speiser et al (1996 ( ) Felix et al (1996 LOH in 1/3 the amino-terminus of the protein have transactivation properties when interacting with target sequences through specific DNA interactions (Fields and Jang, 1990) . Five highly conserved domains have been identified through sequence comparison across species (Soussi et al, 1990) , and these have been termed domains I-V. Conserved domain I is within the transactivation domain. The central part of the protein (amino acids 100-293) encodes the DNA-binding domain, which recognizes and binds a consensus target sequence (El-Deiry et al, 1992) . Conserved domains II-V all reside within this core DNA-binding region. The crystal structure of the core DNA-binding domain has been determined as a large Psandwich acting as a scaffold for two large loops and a loop-sheet-helix, which together make all the interactions with DNA (Cho et al, 1994) . Of tremendous interest from this study was the observation that the loop domains overlap with the highly conserved domains and that the majority of mutations in human tumours fall within the three loop motifs. Three residues (K120, C277 and R280) interact through hydrogen bonds with DNA bases and five (K120, S241, R273, A276 and R283) interact with phosphate groups of the major groove. The arginine residue at codon 248 has four crucial interactions with phosphate groups along the minor groove (Cho et al, 1994; Vogelstein and Kinzler, 1994; Arrowsmith and Morin, 1996) . Two classes of mutation are predicted from knowledge of this structure (Cho et al, 1994) . Contact mutations affect residues that directly contact DNA, including R248 and R273, which are among the most frequently mutated residues. Structural mutations affect residues that do not directly contact DNA but which stabilize the structure of TP53, for example R249 and R175, both of which connect two of the loops.
The C-terminal end of the core DNA-binding domain was shown by Cho et al (1994) to extend from the major groove away from the bulk of the DNA-binding domain. TP53 functions as a tetramer, and residues 324-355 are responsible for oligomerization. The structure of this domain has been deduced from nuclear magnetic resonance (Clore et al, 1994) and X-ray crystallography (Jeffrey et al, 1995) and reveals that the TP53 tetramer is actually a dimer of dimers. This structure fits well the observation that the TP53 binding consensus sequence is a pair of inverted repeats (ElDeiry et al, 1992) . Relatively few mutations have been seen in the tetramerization domain, the majority of which lead to premature termination of the protein (Hollstein et al, 1996) .
The TP53 gene maps to chromosome 17pl3.1, spanning around 20 kilobase pairs (kb), and comprises 11 exons. The coding region spans exons 2-11, with the core DNA-binding domain being encoded by part of exon 4 through to exon 8. As most of the somatic mutations have been found within this core domain, many groups have only analysed exons 5-8 for point mutation. While there is little doubt that mutations within these exons are the most frequent, it has become difficult to assess the frequency of mutations outside this region, and it has been estimated that over 20% mutations remain undetected (Greenblatt et al, 1994) .
In addition to the properties of TP53 described above, wild-type TP53 has been termed the 'guardian of the genome' (Lane, 1992) . Wild-type TP53 functions in checkpoint control after DNA damage (Kuerbitz et al, 1992) , resulting in either a delay in cell cycle progression at the G,/S border to allow DNA repair (Kastan et al, 1991) or apoptosis (Yonish-Rouach et al, 1991) . TP53 has also been implicated directly in DNA repair (Ford and Hanawalt, 1995) and in GC arrest (Paules et al, 1995; Stewart et al, 1995) .
The majority of mutations described in other tumour-suppressor genes such as RB], APC and BRCAI are clearly loss-of-function mutations. The mutation spectrum in these genes shows a high proportion of nonsense and frameshift mutations that produce an absent or truncated protein. Mutations to TP53 are most frequently missense and, while they may lead to loss of certain functions such as failure to arrest in G,/S or G2, they frequently result in the gain of a function such as the ability to cooperate with ras in the transformation of fibroblasts. In addition, certain TP53 mutants may demonstrate a dominant-negative function by, for example, forming oligomeric complexes with wild-type TP53 and blocking its normal functions (Milner and Metcalf, 1991) .
The relatively bewildering spectrum of mutations seen in human tumours coupled to some understanding of the functions of various domains of the TP53 protein has led a number of groups to establish assays to evaluate the relevance of mutations. Many assays are available, including growth arrest of target cells, apoptosis or transactivation of target genes in mammalian cells. Perhaps the most useful assays, and the ones which have additionally been used as a screen to detect the presence of TP53 mutations in both human tumours and the germline, are functional assays in yeast. Initially the assay, based on the inability of the majority of TP53 mutants to transactivate target genes, was established in human cells (Frebourg et al, 1992) . However with the demonstration that mammalian TP53 can function in yeast cells (Scharer and Iggo, 1992) , a simple functional assay was described (Ishioka et al, 1993; Flaman et al, 1995) . This assay will now provide a mechanism by which mutations can be assessed for their transactivation properties. As yet, relatively few mutations have been assessed in this yeast assay, but not all mutations will be detected. The assay relies on high-quality mRNA from the test source, which is reverse-transcribed into cDNA and integrated into a yeast plasmid by homologous recombination in vivo. Codons 67-347 are integrated into the yeast plasmid, therefore any mutations outside these regions will not be detected. In addition, large deletions or insertions may not be detected and nor will any mutations in which there is little or no expression of the mutant transcript (Flaman et al, 1995) .
TP53 MUTATIONS AND LI-FRAUMENI FAMILIES
In the initial study describing the involvement of germline TP53 mutations in LFS, Malkin et al (1990) studied five Li-Fraumeni families and sequenced exons 5-8 in affected individuals from each family. All five families had missense mutations, all within the highly conserved region IV of exon 7. The clustering of mutations within this short region of the protein was confirmed in a further family (Srivastava et al, 1990) , leading to the proposal that there was a restriction upon the mutations in the TP53 gene that are permitted in the germline (Vogelstein, 1990) . However, analysis of eight classic LFS families by Santibanez-Koref et al (1991) revealed that mutations in exon 7 only occurred in two families, and subsequently mutations have been found throughout the gene (see below). Although TP53 mutations have been reported in over 50 Li-Fraumeni families (see Table 1 ), only two studies have analysed consecutively ascertained series of such families. Frebourg et al (1995) have studied 15 families conforming to classic LFS and have identified eight families with germline mutations by screening exons 2-11. Recent data from our own studies (Varley et al, 1997a) , in which all 11 exons plus the promoter region and all splice junctions have been analysed by direct sequencing, has identified 15 germline TP53 mutations in 21 LFS families (71 %) and four mutations in 18 LFL families. From these two studies, it is clear that germline mutations within the coding regions of TP53 are not responsible for all Li-Fraumeni families.
GERMLINE TP53 MUTATIONS IN PATIENTS WITH TUMOURS TYPICAL OF LFS
Since the original description of germline TP53 mutations, there have been a number of studies in which series of patients with tumours characteristic of Li-Fraumeni syndrome have been screened to determine the proportion of those patients who are gene carriers (see Table 1 ). Patients with bone or soft-tissue sarcomas were studied by Toguchida et al (1992) , including 181 cases of sporadic disease and 15 patients with an unusual family history of cancer or multiple primary tumours. Three TP53 germline mutations were detected in the former group, but all were subsequently found to have multiple primary tumours or first-degree relatives with sarcomas. In the group that had been selected, five germline mutations were found (33%), indicating that up to one-third of the patients with sarcoma and either multiple tumours or an unusual family history were carriers of germline TP53 mutations. McIntyre et al (1994) studied 237 unselected children with osteosarcoma and found seven with a germline mutation; Porter et al (1992) reported one germline mutations out of seventeen patients with osteosarcoma and lavarone et al (1992) reported one germline mutation in four patients with multifocal osteogenic sarcoma. Diller et al British Journal of Cancer (1997) 76 (1), [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Cancer Research Campaign 1997
Li-Fraumeni syndrome -a review 5 (1995) examined 33 patients with childhood rhabdomyosarcoma and found three germline mutations, all in the group of 13 children under the age of three (23%). Clearly it is now possible to identify a group of affected individuals with sarcoma at high risk of carrying a germline TP53 mutation. The occurrence of sarcomas (particularly rhabdomyosarcomas) in young children, an unusual family history or multiple primary tumours should warrant an examination for a germline TP53 mutation. From studies already published, it appears that up to one-third of this group may be carriers.
A number of studies have also been carried out on patients with brain tumours. Kyritsis et al (1994) found TP53 mutations in nine of 51 patients with glioma, all of whom had either multifocal disease or a family history of cancer. Other studies have found germline TP53 mutations in around 2-10% of cases of brain tumour, with the highest frequency in gliomas in children or young adults with an unusual personal or family history of cancer (Chung et al, 1991; Chen et al, 1995; Felix et al, 1995; Li et al, 1995) .
Premenopausal breast cancer is very common in Li-Fraumeni families, and three groups have examined series of sporadic breast cancer patients for germline TP53 mutations Prosser et al, 1992; Sidransky et al, 1992) . Only four mutations were detected in a total of 499 patients studied by these three groups, indicating that TP53 mutations are responsible for no more than 1% of breast tumours. All four patients showed very strong family histories of cancer. Although frequently overlooked, patients with germline TP53 mutations contribute significantly to the number of breast cancer cases with a strong inherited component, particularly when breast cancer is diagnosed at a very young age (< 30 years). It has been estimated that around 1% of breast cancer cases between the ages of 30 and 40 years arise within Li-Fraumeni families . This is clearly lower than the proportion of early-onset cancers due to either BRCA I or BRCA2 but is nonetheless significant. Wagner et al (1994) examined children with adrenocortical carcinoma (ACC) and, although the numbers are small, three of six had germline TP53 mutations. Selection of families on the basis of an ACC also indicated a very high frequency of mutations (Sameshima et al, 1992) . In the Li-Fraumeni families that we have studied to date, all five in which there is an adrenocortical tumour have a germline TP53 mutation, and there are no cases of ACC in any negative family (Varley et al, 1997a) .
Finally, studies of patients selected on the basis of multiple primary tumours Shiseki et al, 1993; Russo et al, 1994) have shown that they have germline TP53 mutations at a frequency of between 7% and 20%.
Although Li-Fraumeni families are rare, nonetheless germline TP53 mutations are frequent in individuals with specific cancers, particularly at young age. Half of all cases of childhood ACC and between one-quarter and one-third of childhood sarcomas, particularly multifocal or with a family history, arise in patients with a germline TP53 mutation. Any patient presenting with such tumours, especially if there is additional personal or family history of malignancy, should be considered as a potential mutation carrier. This could have profound implications for both the treatment of the patients and their subsequent monitoring and for analysing TP53 for mutation with a view to offering other family members predictive tests. This will be discussed in more detail later in this review. It should also be noted that in the majority of studies cited above, analysis of TP53 has not covered the entire coding region and, if this were carried out, the frequency of germline mutations within various groups of cancer patients may rise.
THE SPECTRUM AND TYPE OF GERMLINE TP53 MUTATIONS
There are now over 50 families reported that conform to the definition of classic LFS or LFL, using the definition of Birch et al (1994a) , and in whose members germline TP53 mutations have been found (Table 1) . From the literature, the proportion of families that do not have a detectable coding mutation is not generally clear. There have been only two studies in which there has been a systematic analysis of TP53 in series of families (Birch et al, 1994a; Frebourg et al, 1995; Varley et al, 1997a) , and both of these studies have identified families in which there is no coding mutation. Frebourg et al (1995) found 7 of 15 LFS families to have no mutation, although they did not examine exon or the promoter region. In our own series (Varley et al, 1997a) , we found mutations in 71% of classic LFS families. There are many reports in the literature of single families in which a mutation has been found, but it is not possible to determine how many families have been examined and found to be negative; however, it seems likely that at least 30% of LFS families have no coding mutation. There is only one definite report of a Li-Fraumeni family in which the syndrome was unlinked to TP53 (Birch et al, 1994b) , although normal tissues from affected individuals within this family have been shown to express elevated levels of TP53. The only other family in which there appeared to be no TP53 mutation but overexpression in normal tissues (Barnes et al, 1992) has been subsequently shown to have a mutation in the tetramerization domain encoded by exon 10 (Lomax et al, 1997). There have been reports that in some negative families the expression of TP53 is limited to one allele, implicating a possible regulatory mutation in some Li-Fraumeni families (Li and Fraumeni, 1994) .
We are aware of 114 reports of germline TP53 mutations (see Table 1 ), ascertained by analysis of LFS or LFL families, as well as others such as breast Prosser et al, 1992; Jolly et al, 1994; Shay et al, 1995; Sun et al, 1996) or brain (Lubbe et al, 1995) site-specific families or cohorts of patients with tumours typical of Li-Fraumeni syndrome (see above). The spectrum of mutations shows that the majority of all germline mutations cluster in exons 5-8, however this is undoubtedly skewed because most studies only examine these exons. In our own study, of 19 mutations found to date, five fall outside these exons (26%; Varley et al, 1997a) . This finding has profound implications for genetic testing within Li-Fraumeni families, and we recommend that all exons, both coding and non-coding, plus all splice junctions and the promoter region are analysed.
We have analysed all the reported germline mutations to determine the mutation type. There is no difference in the frequency of missense and nonsense mutations between Li-Fraumeni families, other types of families and individuals with no family history. In addition, there are no differences between LFS and LFL families.
There are two reports of large germline deletions, one involving the whole of exon 10 (Plummer et al, 1994) and the other removing 167 bp, including part of exon 1 and intron 1 (Varley et al, 1997a) . Both of these deletions were flanked by short direct repeat sequences. Thirteen other mutations involve short insertion or deletion events (Sameshima et al, 1992; Toguchida et al, 1992; Felix et al, 1993; Birch et al, 1994a; Hamelin et al, 1994; Mazoyer et al, 1994; Stolzenberg et al, 1994; Lubbe et al, 1995; Felix et al, 1996; Varley et al, 1996a Varley et al, , 1997a 1994). Although deletions and insertions are most frequent in exons 2-4 and 9-11 in sporadic tumours (Harris, 1996) , in the 114 germline mutations we have reviewed, the situation is not as straightforward. There is only one report of a mutation in exon I (Varley et al, 1997a) , which is a large deletion, and there are no reported mutations in exons 2 and 3. Two of the six mutations in exon 4 are deletions or insertions. One of the three mutations reported in exons 9-11 is a large deletion (Plummer et al, 1994) . Deletions or insertions therefore constitute a significant proportion of the mutations in exons 1-4 and 9-11 in germline tumours, as seen in sporadic tumours. However, six of the 14 mutations reported in exon 6 are deletions or insertions at short repeat sequences, with all except one leading to a frameshift and premature termination. Harris (1996) suggests that deletions or insertions in sporadic tumours are more frequent in exons 2-4 and 9-11 because the regions of the TP53 protein encoded by these exons generally require more than one mutation to abrogate function, and this is most efficiently caused by a deletion or insertion event. Why these events are seen at such a high frequency in exon 6 as germline mutations is unclear at present. Thirteen of the 15 deletion or insertion events were found in patients with a strong family history, twelve with family histories compatible with Li-Fraumeni syndrome (see Table 1 ).
In all reports of germline TP53 mutations, transitions are the most common change, accounting for 66% of all germline mutations, with those within CpGs being the predominant type (44% of all mutations). These types of mutation are considered to represent endogenous events. Cytosine and 5-methylcytosine can spontaneously deaminate to uracil and thymine, respectively, resulting in G:C to A:T transitions. The majority of transitions occur at CpG dinucleotides, which are common sites for methylation, and transitions can also occur as a result of replication errors. When the frequency of transitions in patients with any family history of cancer is compared with that in patients with no family history, there is an under-representation of transitions at CpG in the latter group (P < 0.004). In this and subsequent analyses, we scored patients as having a family history if they had at least one firstdegree relative with cancer under the age of 60 years or if they had a family history compatible with LFS or LFL. There was no difference in the frequency of transitions between patients with a family history compatible with LFS or LFL and all other patients with or without a family history.
Transversions represent 21 % of all germline mutations. Transversions can occur as a result of replication errors but are also considered to represent the possibility of exogenous carcinogenic insult. G residues are a common target for bulky carcinogeninduced adducts, resulting in stalling of the replication machinery and misincorporation by DNA polymerase. We therefore analysed the data on the 114 germline mutations to determine whether there was a difference between the frequency of transversions in patients with a strong family history and those without a family history. Whereas only 11 transversions were seen in 81 cases (14%) when there was a strong family history, 13 of the other 33 cases (without a family history) had transversion mutations (39%). This difference is statistically significant (P < 0.005) and raises the possibility that the majority of germline mutations that have arisen recently may be due to exposure to carcinogens. A more detailed collaborative epidemiological study would be required to address this possibility. Intriguingly, when patients with germline mutations are separated into LFS or LFL family members vs others (both with and without a family history), the difference in the frequency of transversions is still significantly different (P < 0.02), and an increased occurrence of deletions or insertions in LFS or LFL families reaches significance (P < 0.03).
GENOTYPE-PHENOTYPE CORRELATIONS AND PENETRANCE
The finding that around 30% of classic LFS families and a higher percentage of LFL families have no TP53 coding mutation raises the question as to whether there may be phenotypic differences between those families with and those without identifiable mutations. Although there are numerous reports of individual families or patients, or groups of families and patients, with germline TP53 mutations, there are only two published series of families in whom the entire coding sequence of TP53 has been analysed Varley et al, 1997a) , with only the latter study including an analysis of exon 1 and the promoter region. Furthermore, in the study by Frebourg et al (1995) , details of the pedigrees of the families included in the study were not published. The only series in which it is possible to analyse the cancer phenotype in LFS and LFL families with and without germline TP53 mutations is that assembled by our own group. In 30 of the families in whom sequence analysis of the entire TP53 gene has been completed (18 LFS and 12 LFL) , histopathological review of tumours has been carried out. The distribution of cancers by morphological type and age at diagnosis has been analysed in these families. The analysis included cancers in the probands and their first-and second-degree relatives. Twelve of the 18 LFS and four of the 12 LFL families carried germline TP53 mutations. In these 16 families, mutation status was determined in as many family members as possible, but all cancers in eligible relatives as defined above were included in the analysis, regardless of whether or not mutation status had been determined in the individual concerned. This strategy ensured comparability between the mutation-positive and -negative families. In total, 116 cancers in LFS and LFL families have been included in the analysis (Table 2) .
When the distribution of cancer cases in the 30 LFS and LFL families overall is analysed, there was a higher proportion of sarcomas in LFS families, but this can be attributed to the requirement of the classic LFS criteria for a proband with sarcoma. If sarcomas are excluded, then the distribution of first primary tumours in LFS and LFL families is very similar. In LFS families, 40% of the non-sarcoma cancers were carcinomas of the breast compared with 39% in LFL families; the figures for brain tumours were 18% and 22% respectively. In both sets of families, the age distribution at diagnosis of cancer was strikingly young. In LFS families, 56% of the cancer cases were diagnosed under age 30 years and 100% under age 50 years; in LFL families the figures were 44% and 78% respectively. In the general population, only 2% of cancer cases occur under 30 years of age and 11% under 50 years of age (data derived from cancer registrations for England and Wales, 1991, Office of National Statistics, September 1996). When the two sets of families were divided on the basis of the presence or absence of a germline TP53 mutation, it was found that overall the cancer cases in families with germline TP53 mutations had a somewhat earlier age of onset, but this was not particularly marked (median age of onset of cancer in LFS and LFL families with germline TP53 mutations is 27 years and in those without mutations is 31 years). The proportions of sarcomas and breast cancers in the TP53-positive and -negative families are very similar (sarcomas in positive vs negative families is 29% vs 31%, respectively, and breast cancers 28% vs 27% respectively; see Table 2 ). However, the age distributions of these cancer cases in the two sets of families did differ. Thus 85% of soft tissue sarcomas in mutationpositive families were diagnosed when the individual was under 20 years of age compared with 50% in the mutation-negative families. For breast cancer, 79% were diagnosed under 40 years in the mutation-positive families compared with 39% in the negative families.
Considering other types of cancers, there was a distinct excess of brain tumours in the TP53-positive families, 19% of all cancers in the mutation-positive families were brain tumours compared with only 6% in the negative families, and 81 % of all brain tumours in the entire series of families occur in those with germline TP53 mutations. All five adrenocortical tumours in the series occurred in families with mutations. However, there appeared to be a deficit of leukaemias and lymphomas in the mutation-positive families, with less than 2% of the cancers in these families being of these types compared with 10% in the mutation-negative families.
The above analyses were based on first primary cancers only. The occurrence of multiple primary cancers in members of Li-Fraumeni families is well described, and there was a similar proportion of individuals with second and subsequent primary tumours in the TP53 mutation-positive and -negative families.
However, in the mutation-positive families sarcoma was the most common second primary, whereas in the negative families breast cancer was the most common.
The data reported above are incomplete as diagnostic review of cancers in the entire series of families is still in progress. However, on the basis of these preliminary analyses there do appear to be phenotypic differences between Li-Fraumeni families with and without germline TP53 mutations. 'Marker' cancers for the presence of such mutations in both LFS and LFL families appear to be early-onset soft-tissue sarcoma, in particular rhabdomyosarcoma diagnosed under the median age of diagnosis for all childhood rhabdomyosarcomas (under 4 years), adrenocortical carcinoma, breast cancer aged under 40 years, and brain tumours in children and young adults. Histological examination of the CNS tumours that occurred in carriers of TP53 germline mutations in our series showed them to be mainly high-grade astrocytoma or glioblastoma and childhood medulloblastoma. Results of the formal analysis of cancer phenotype in the entire series of families examined by us may have important implications for counselling and future screening regimens in families both with and without germline TP53 mutations.
In those families with germline TP53 mutations, it will also be important in relation to genetic counselling and disease screening to have reliable estimates of penetrance and age-specific risks for the various component cancers of the syndrome. At present, there are insufficient data to provide such estimates. However, preliminary data do exist that could provide some guidance. On the basis of population studies of cancer risks in families of children with sarcoma and follow-up studies in families with LFS, it has been shown that the risk of cancer is elevated up to, but not beyond, age 60 years (Birch et al, 1990; Garber et al, 1991) . Using a data set comprising details of occurrence of cancer among the close relatives of a hospital-based series of children who had survived sarcoma, Lustbader et al (1992) conducted a segregation analysis. This demonstrated that the distribution of cancer in the families was consistent with a rare autosomal dominant gene (frequency 0.00002) with penetrance of approximately 50% by age 40 years and up to 90% by age 60 years. The age-specific penetrance was higher in women than in men because of breast cancer occurrence. It is likely that the major component of the familial cancer clustering detected by Lustbader et al (1992) was due to TP53 but there is a possibility that other genes such as BRCA2 and NFI may be making small contributions. This should be borne in mind when interpreting these results.
The only published estimates of age-specific risks associated with germline TP53 mutations were based on only five families but used a new method which addresses the problem of ascertainment bias (LeBihan et al, 1995) . Risks were estimated to be 42% between ages 0 and 16 years, 38% between ages 17 and 45 years and 63% after age 45 years; lifetime risk was estimated to be 85% (LeBihan et al, 1995) . Although these results should be viewed with caution, because they are based on such small numbers, the method should prove to be useful in analysing larger series. This requires international collaboration, and such a study is planned.
LOSS OF HETEROZYGOSITY STUDIES IN TUMOURS FROM PATIENTS WITH GERMLINE TP53 MUTATIONS
Wild-type TP53 is considered to be a tumour-suppressor gene (Hollstein et al, 1991; Levine et al, 1991; Lane, 1992 ) and as such a number of tumours of a variety of types from patients with germline TP53 mutations have been analysed for loss of heterozygosity (LOH). LOH at a particular locus/gene is considered to indicate the presence of a tumour suppressor at that locus (Ponder, 1988) , with the LOH event unmasking the recessive mutation.
Tumour-suppressor genes such as BRCAJ , RBI (Cavenee et al, 1983) , BRCA2 (Gudmundsson et al, 1995) , APC (Ichii et al, 1992) and VHL (Tory et al, 1989) have been studied in many families in which there is a germline mutation to those genes, and loss of the wild-type allele has been seen at high frequency in the tumours of patients carrying the mutation. All these genes therefore fulfil the criteria expected of tumoursuppressor genes, namely obeying Knudson's 'two-hit' hypothesis (Knudson, 1971) , whereby one defective allele is inherited and the second is inactivated by loss of part or all of the wild-type chromosome (Ponder, 1988) .
To our knowledge 82 tumours from patients with germline mutations at TP53 have been studied for LOH, with LOH detected British Journal of Cancer (1997) 76(1), [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] in 57% of those tumours (see Table 2 ; Varley et al, 1997b ). This figure is lower than expected from a comparison of the loss of other tumour-suppressor genes in inherited cancer syndromes, in which levels of 80% LOH are not unusual. However, only one systematic study of LOH has been carried out in a large series of patients with defined TP53 mutations in tumour material that has been characterized according to current standard criteria (Varley et al, 1997b) ; most other studies have involved examination of LOH in a single family and/or a very few tumours. In the former study, LOH was observed in only 44% of tumours, but a number of interesting patterns of LOH were described. All tumours except breast in which there was a codon 248 mutation showed retention of the wild-type allele. Only one other tumour described in the literature with a codon 248 mutation has been analysed for LOH and that also failed to show LOH (Scott et al, 1993) . This finding is discussed in more detail in Varley et al (1997b) , but it is not obvious why there should be no loss of the wild-type allele in the presence of a codon 248 mutation, whereas a variety of tumours with a range of other mutations do show LOH. If tumours with codon 248 mutations are excluded from the analysis, LOH is seen in 60%, which is still lower than that seen for other tumoursuppressor genes. However, it is possible that there is underreporting of LOH, with contamination of the tumour sample with normal cells accounting for the number of cases in which there is apparently no LOH. In the consecutive series in which all tumours were assessed to ensure a high percentage of tumour cells before analysis, LOH was also seen in only 60% of cases (excluding those with a codon 248 mutation; Varley et al, 1997b) . The figure of 60% LOH is therefore consistent among the different studies and reflects the true level of LOH.
LOH has been seen in a number of benign or premalignant lesions, including ductal carcinoma in situ of the breast and endometrial hyperplasia (Varley et al, 1996a) and an adrenocortical tumour (Varley et al, 1995) . More surprisingly, loss of the mutant allele has been seen in three cases Varley et al, 1997b) .
To date, of four reports in which LOH has been examined in gastric/stomach tumours, all showed retention of the wild-type allele (Scott et al, 1993; Horio et al, 1994; Varley et al, 1997b) . In contrast, of thirteen breast tumours studied, LOH was seen in ten (Malkin et al, 1990; B0rresen et al, 1992; Prosser et al, 1992; Srivastava et al, 1992; Warneford et al, 1992; Eeles et al, 1993; Varley et al, 1997b) . We have examined other markers on chromosome 17 in five breast tumours showing LOH at TP53 and have demonstrated that the loss seen is not targeting more distal candidate tumour-suppressor loci on the short arm of chromosome 17 nor loci on the long arm (Varley et al, 1997b) .
The relatively low level of LOH seen in tumours from patients with germline TP53 mutations compared with the levels of loss seen of other genes in inherited cancer syndromes is not entirely surprising given the range of functions of TP53 as described above. It could be considered that gain-of-function mutants or those showing dominant-negative features may be sufficient to induce tumour formation in the presence of the wild-type gene. Why this should be so in tumours in patients with an inherited mutation when the situation is different in sporadic tumours remains unclear. Recent data from studies of TP53-deficient mice demonstrate that 40-50% of tumours that develop in heterozygous null mice do not show LOH and that the retained allele has the properties of wild-type TP53 (LA Donehower, personal communication; Shi et al, 1997) .
FUNCTIONAL STUDIES OF LI-FRAUMENI CELLS
There have been many studies carried out to examine the altered function(s) of the variety of TP53 mutations that occur in human tumours. Many of these studies involve the introduction of mutant TP53 constructs into cells that either contain an endogenous wildtype TP53 gene or that are null for TP53. Frequently the mutant TP53 gene is overexpressed, and a number of functional end points are examined. These studies all suffer from a common drawback: the genetic background in which the assays take place does not reflect that of a normal cell from a patient with a germline TPS3 mutation. For this reason, a number of groups have examined cells derived from patients with germline TP53 mutations, most commonly lymphoblastoid or fibroblast cell lines.
Fibroblasts from Li-Fraumeni patients show chromosomal sensitivity (measured by an increased frequency of chromosome aberrations) to the effects of ionizing radiation (Parshad et al, 1993) , in contrast to the cellular radioresistance (measured by cell survival) observed by Bech-Hansen et al (1981) and our own group (Sproston et al, 1996) . Chromosomal radiosensitivity has also been observed in lymphocytes from Li-Fraumeni patients (D Scott, personal communication The above studies were all carried out on relatively earlypassage heterozygous (i.e. wild type/mutant) fibroblasts that had been treated with a DNA-damaging agent of some sort, usually irradiation. However Li-Fraumeni fibroblasts that are maintained in culture and not subjected to any damaging agents also show a range of abnormalities. As they are cultured through progressive population doublings, they show an increased number of chromosome abnormalities of all types Yin et al, 1992; Rogan et al, 1995) , loss of the wild-type allele (Yin et al, 1992; Rogan et al, 1995) , changes in morphology and, rarely, spontaneous immortalization Rogan et al, 1995) accompanied by telomere elongation (Rogan et al, 1995) . Spontaneous immortalization has also been reported in breast epithelial cells from a LFS patient with a germline TP53 mutation (Shay et al, 1995) , and even Li-Fraumeni cells that fail to immortalize spontaneously can be induced to do so by treatment with various agents that have no effect on normal cells (Shay et al, 1995; Tsutsui et al, 1995) .
The loss of wild-type TP53 from Li-Fraumeni fibroblasts correlates in vitro with failure to arrest in GI when treated with a uridine biosynthesis inhibitor PALA and subsequent PALA-selected gene amplification (Livingstone et al, 1992; Yin et al, 1992 ). This phenotype is reversible upon reintroducing a wild-type TP53 construct into the fibroblasts. PALA reduces the intracellular pool of nucleotides, and inappropriate entry of cells into S-phase after PALA treatment as a result of the failure to arrest in G, could result in chromosome breakage or fragmentation and could initiate gene amplification (Yin et al, 1992) , which is one manifestation of genomic instability. PK Liu et al (1996) have examined other
British Journal of Cancer (1997) 76 (1) (1995) showed that the cells retained a normal induction of p21wafl and MDM2 upon DNA damage and maintained genomic stability and that there was no loss of the wild-type TP53 allele in heterozygous cells even after 1 year in culture. Williams et al (1996) showed that the presence of a heterozygous TP53 mutation had no effect on TP53 expression after DNA damage or on G,/S arrest. There are clearly differences in the phenotype of unstimulated lymphocytes from patients with germline TP53 mutations, such as an abnormal apoptotic response (Camplejohn et al, 1995) , and it is possible that the immortalization by EBV is influencing the behaviour of these cells in a TP53-independent manner. However, the data may also suggest that the different tissue-specific phenotypic responses to the presence of a heterozygous TP53 mutation could account for the spectrum of tumour types observed in patients from Li-Fraumeni families (Lalle et al, 1995; Williams et al, 1996) .
To summarize all the data obtained from many different studies, the presence of a germline TP53 mutation in the heterozygous state appears to permit the accumulation of genetic damage, leading to genomic instability and eventually neoplastic transformation. However, although a range of tumour types is seen in Li-Fraumeni families, many common solid tumours are not represented to a significant degree (e.g. colorectal tumours and gynaecological malignancies), and the reason for the limited spectrum of tumours remains unclear.
One important feature of all the above studies in Li-Fraumeni cells is that they are extremely sensitive to DNA damage of any sort. This has considerable implications for the clinical management of patients in Li-Fraumeni families, particularly in screening for cancers and for treatment. While the frequency of radiationinduced tumours is still not known in germline mutant TP53 carriers, there is evidence that second malignant neoplasms occur at a relatively high frequency in the radiation zone (Strong and Williams, 1987; Heyn et al, 1993) , although more extensive studies must be carried out to confirm this. The relative contributions of genetic background and radiation remain to be evaluated in a careful epidemiological study.
ANIMAL MODELS OF LI-FRAUMENI SYNDROME
The earliest study in which a TP53-transgenic mouse was generated was described in 1989 (Lavigueur et al, 1989) , before the genetic basis of LFS was elucidated. The observed occurrence of multiple tumours in the transgenic strains, including tumours typical of LFS, contributed towards the decision to study TP53 as a candidate gene by Malkin et al (1990) . These transgenic mice carried their normal wild-type TP53 alleles as well as high numbers of copies of a mutant transgene, and tumours developed in 20% of the transgenic mice, commonly osteosarcomas and lung adenocarcinomas but also lymphomas and a range of other tumours. Interestingly, the levels of expression of the mutant transgenes did not correlate simply with the sites of tumour formation. Donehower et al (1992) reported the generation of transgenic knockout mouse strains that were homozygous null for TP53, with part of intron 4 and exon 5 replaced with a neo gene. These mice were, surprisingly, viable and initially appeared to have no developmental abnormalities. Three-quarters of the homozygous null mice developed tumours by 6 months of age, predominantly lymphoblastic lymphomas but also sarcomas. The same group (Harvey et al, 1993) extended these studies to examine heterozygous null/wild-type mice, which reflects more accurately the situation in some LFS families. In contrast to the situation in homozygous null mice in which 100% had developed tumours or died by 10 months of age, only 50% of heterozygotes had developed tumours by the age of 18 months. The spectrum of tumours differed between the two groups, with 58% of the heterozygotes developing sarcomas (predominantly osteosarcomas) and only 32% developing lymphomas (Harvey et al, 1993) (Armstrong et al, 1995; Sah et al, 1995) .
TP53-deficient mice are extremely sensitive to gamma irradiation with a reduced tumour latency following low-level irradiation (Kemp et al, 1994) . This sensitivity is associated with an increase in radiation-induced double-strand chromosomal breaks . Transgenic mice carrying mutant TP53 genes show cellular radioresistance in haematopoietic cells (Lee and Bernstein, 1993 (Nishino et al, 1995; Sands et al, 1995) .
In many respects the transgenic and TP53-deficient mice are good models for Li-Fraumeni syndrome. However none of the mouse strains generated to date is a perfect model, particularly with respect to the spectrum of tumours seen in these animals. The targeted introduction of a specific point mutation into one allele in a heterozygous mouse would be of great interest.
CLINICAL ASPECTS OF LI-FRAUMENI FAMILIES
The definition of classic LFS, like the Amsterdam criteria for HNPCC (B Liu et al, 1996) , seems to be a good predictor for mutations in the causative genes TP53 and the HNPCC mismatch repair genes respectively. The definition is therefore useful in genetic counselling as it allows the counsellor to talk in purely Mendelian terms. In our series (Varley et al, 1997a) , TP53 mutations have been detected in 71% of families with classic LFS, and it is possible that a high proportion of families with no detectable TP53 mutation have functional loss. Our data, together with those of other groups (Sameshima et al, 1992; Wagner et al, 1994; Diller et al, 1995) (Lustbader et al, 1992) .
LFL families are more difficult. Using our own definition (Birch et al, 1994a) , under 25% will have a detectable TP53 mutation. A proportion may be due to other genes, but some may be due to chance association. It is not possible, therefore, to counsel in terms of a 50% risk for relatives of affected cases or to make firm predictions about the likely tumour spectrum for at-risk individuals. Some of these family aggregates may be due to a recent new mutation and some latitude with the criteria, particularly if the family includes childhood ACC or rhabdomyosarcoma, may well predict a high proportion of the TP53-positive LFL families. Once a mutation has been detected genetic counselling becomes straightforward, but the absence of a mutation does not allow complete reassurance.
In common with current practice in breast cancer families, predictive presymptomatic testing should not be offered to at-risk individuals unless a TP53 mutation has already been identified in an affected individual. Although mutations can be found in DNA extracted from paraffin-embedded tumour material, the DNA is often of poor quality. The DNA may fail to amplify certain exons of TP53 and, if non-sequencing mutation detection methods are used, certain mutations can be missed (see Varley et al, 1995) .
Tumours may also of course contain a somatic mutation and this possibility would have to be excluded by finding the identical mutation in multiple tumours from the same or related individuals. Only if the mutation was confirmed in this way could it be used in predictive testing. In practice, therefore, it is usually necessary to have a living affected individual on whom to undertake mutation analysis. As described above, 26% of mutations occur outside the accepted hotspots, and therefore the whole gene needs to be sequenced in each case. Mutations that truncate the protein or that are accepted as affecting key properties of TP53 from functional studies, or their presence either in other Li-Fraumeni families or commonly in human tumours, can be used in predictive testing. However predictive testing using missense or splice-site mutations outside the above categories should be undertaken with extreme caution. Even if other affected family members test positive for the same sequence variant, this could still represent a rare polymorphism and, if possible, some functional studies should be carried out to determine relevance of the alteration. However, if many affected family members are positive for the 'mutation' and, especially if there is loss of the wild-type allele in tumour tissue, then testing would be reasonable.
Our own early experience and that of others (Schneider et al, 1995) would suggest that uptake of testing will be relatively low. Once an individual is availed of the risks to a mutation carrier and the paucity of options with regard to early detection and prevention, they may prefer to live with the better-than-even chance that they will not carry the mutation. (Their 50% risk will have been reduced, assuming they have reached adulthood by the time of counselling.) Nonetheless a significant minority proceed to testing and will require extra support both psychologically and in terms of extra surveillance if they test positive. It is vital that individuals are given adequate time for reflection before taking the test and therefore testing protocols should be similar to those adopted for Huntington's disease Eeles, 1993; Birch, 1994) . It is widely accepted that testing of children should not be offered routinely; however, parents may exert considerably pressure to have a child tested. Each case should be treated on its own merits. If the case can be answered that the child is likely to benefit from the test, then after very careful counselling that includes the child or children, proceeding to testing may be appropriate in some isolated cases. We have been involved in tests on four children over 10 years of age, one of whom was mutation positive. Although follow-up is still early, all the children and families seem to have benefited from testing. Nonetheless, long-term effects such as insurance and other discrimination on TP53-positive individuals may deter most genetic counsellors and parents from testing children.
Given the wide diversity and unpredictability of tumours in Li-Fraumeni syndrome, no widely accepted screening procedure has been devised. It may be wise to avoid as far as possible any radiological screening that exposes the patient to excessive ionizing radiation. However one of the few organs that could be targeted for screening, i.e. the breast and full blood count to children and a specialist breast examination with or without ultrasound to women over 20 years. Selective screening, such as cranial MRI in families with brain tumours or gastroscopy in families with gastric carcinoma, could also be justified, although their effectiveness is not known.
Some women in LFS families have undertaken preventative mastectomy (DGRE, unpublished data). However this does not allow the same level of reassurance as in BRCAJ and BRCA2 carriers as so many other organs are at risk. Families are therefore pinning a great deal of hope on genetic therapies. Germline gene therapy, even if it were possible, has not been approved by any regulatory authority. Even selective/tissue-specific targeting of treatment is still beyond our current capabilities. Nonetheless, the outcome of many clinical trials involving the manipulation of TP53 is eagerly awaited. This will probably have more implications for treatment of tumours than in prevention, but any procedure reducing mortality in Li-Fraumeni syndrome would be gratefully accepted by the families. There is a general assumption that tumours in carriers of germline TP53 mutations may be relatively radiation resistant, although hard data are not available and there appears to be a high risk of second malignancy in the radiation field (Strong and Williams, 1987; Heyn et al, 1993) . However, more extensive longitudinal studies on germline TP53 mutation carriers are necessary to assess the effectiveness of current treatment regimens.
It should be stressed that counselling, genetic testing and screening for early detection of cancers in Li-Fraumeni families are in their infancy. Although some data are available on agespecific risks of cancers associated with Li-Fraumeni syndrome, at present the estimated risks are based on very small numbers of cancer-affected individuals. Furthermore, families in whom TP53 mutation analysis has been undertaken were selected because of their striking patterns of cancer. In the circumstances, it is recommended that any such counselling, testing and screening should only be undertaken in centres experienced with both clinical aspects of the syndrome and with expertise in sequence analysis of the entire TP53 gene. Of equal importance, families in whom TP53 mutation analysis is undertaken should be included in a research programme encompassing molecular genetic, genetic epidemiological, clinical and psychosocial aspects. It is only by applying such a systematic approach and with international collaboration that progress will be made.
CONCLUDING COMMENTS
Although families conforming to the strict definitions of classic LFS or LFL are very rare, germline TP53 mutations may be relatively common in certain groups of cancer patients. The definition of classic LFS is still of great value in clinical practice and predictive testing but may need to be modified to take into account the occurrence of tumours such as adrenocortical carcinomas. In view of the potentially damaging effects of radiation on cells with TP53 mutations, considerable care should be taken when screening patients with germline mutations for tumours, and the design and implementation of novel screening protocols is of some urgency. Studies of cells from patients with germline mutations have provided, and will continue to provide, insight into the function(s) of TP53, and further characterization of families with no detectable coding mutation may identify germline mutations in other genes involved in the same pathway(s).
